IL318916A - FC variants with improved binding to FCRN and extended half-life - Google Patents

FC variants with improved binding to FCRN and extended half-life

Info

Publication number
IL318916A
IL318916A IL318916A IL31891625A IL318916A IL 318916 A IL318916 A IL 318916A IL 318916 A IL318916 A IL 318916A IL 31891625 A IL31891625 A IL 31891625A IL 318916 A IL318916 A IL 318916A
Authority
IL
Israel
Prior art keywords
fcrn
variants
life
enhanced binding
prolonged half
Prior art date
Application number
IL318916A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL318916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL318916A publication Critical patent/IL318916A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL318916A 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life IL318916A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (1)

Publication Number Publication Date
IL318916A true IL318916A (en) 2025-04-01

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
IL318916A IL318916A (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life
IL276286A IL276286B2 (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL276286A IL276286B2 (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Country Status (15)

Country Link
US (1) US20190263934A1 (enExample)
EP (1) EP3743441A1 (enExample)
JP (3) JP7399880B2 (enExample)
KR (2) KR20250008975A (enExample)
CN (3) CN119350481A (enExample)
AU (2) AU2019212638B2 (enExample)
BR (1) BR112020015006A2 (enExample)
CA (1) CA3089602A1 (enExample)
CO (1) CO2020010269A2 (enExample)
IL (2) IL318916A (enExample)
MX (2) MX2020007882A (enExample)
MY (1) MY203898A (enExample)
PH (1) PH12020551134A1 (enExample)
SG (1) SG11202006905YA (enExample)
WO (1) WO2019147973A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
CN114466663B (zh) * 2019-07-25 2026-01-02 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
JP7832123B2 (ja) * 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
WO2022090469A2 (en) * 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
WO2023021169A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US20240409618A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
JP2026513101A (ja) 2022-10-25 2026-04-23 アブリンクス エン．ヴェー． エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド
TW202432602A (zh) 2022-12-05 2024-08-16 法商賽諾菲公司 運鐵蛋白受體結合蛋白
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
TW202619716A (zh) 2024-07-23 2026-05-16 法商賽諾菲公司 Ｃｅｒｅｂｌｏｎ連接酶調節劑與ｂｃｍａ ｎｋ細胞銜接子的組合療法
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8775090B2 (en) * 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) * 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CA3032820A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada

Also Published As

Publication number Publication date
CO2020010269A2 (es) 2020-12-10
CN111788221B (zh) 2026-02-13
MX2025009543A (es) 2025-09-02
IL276286A (en) 2020-09-30
TW201940512A (zh) 2019-10-16
JP2021511830A (ja) 2021-05-13
MY203898A (en) 2024-07-23
NZ767453A (en) 2025-03-28
CN119350481A (zh) 2025-01-24
JP2024026255A (ja) 2024-02-28
CN111788221A (zh) 2020-10-16
MX2020007882A (es) 2020-12-03
IL276286B2 (en) 2025-07-01
JP7399880B2 (ja) 2023-12-18
JP7860946B2 (ja) 2026-05-18
RU2020128177A (ru) 2022-02-28
CA3089602A1 (en) 2019-08-01
BR112020015006A2 (pt) 2020-12-29
KR20200115568A (ko) 2020-10-07
CN122145612A (zh) 2026-06-05
AU2019212638B2 (en) 2025-04-03
SG11202006905YA (en) 2020-08-28
KR20250008975A (ko) 2025-01-16
KR102748986B1 (ko) 2025-01-02
PH12020551134A1 (en) 2021-05-31
AU2025204826A1 (en) 2025-07-17
WO2019147973A1 (en) 2019-08-01
IL276286B1 (en) 2025-03-01
EP3743441A1 (en) 2020-12-02
JP2026021377A (ja) 2026-02-10
AU2019212638A1 (en) 2020-09-17
US20190263934A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
IL276286A (en) FC variants with improved binding to FCRN and extended half-life
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
IL274371A (en) Compounds that bind CD137 and PSMA
IL311544B1 (en) Tagmentation using immobilized transposomes with linkers
SG11202007578SA (en) Antibodies binding to gprc5d
IL272561A (en) Engineered antibody fc variants for enhanced serum half life
ZA202003612B (en) Engineered immunoglobulins with altered fcrn binding
EP3835318C0 (en) FC REGION VARIANTS WITH MODIFIED FCRN AND PROTEIN LIGAND PROPERTIES MAINTAINED
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL240606B (en) A fcrn-binding polypeptide comprising an fcrn-binding motif (bm) and various aspects related thereto
GB2549632B (en) Fusion protein comprising three binding domains to 5T4 and CD3
DK3215528T3 (da) Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
PL3355913T3 (pl) Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
MX379475B (es) Inmunocitocinas variantes de il-2 dirigidas a tumores en combinación con anticuerpos contra pd-l1 humana para usarse como terapia de combinación.
ZA201708613B (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
IL269394A (en) Antibodies bind to STEAP-1
IL266516B (en) An antibody that specifically binds to cd66c and its use
EP3247746A4 (en) Acrylic elastomeric resin composition and file prepared using the same
HK40035029A (en) Fc variants with enhanced binding to fcrn and prolonged half-life
GB2574206B (en) Briquettes
PL3081609T3 (pl) Bitumiczne spoiwo klejące i jego zastosowanie
PL3362480T3 (pl) Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie
EP3903032A4 (en) MULTIFUNCTIONAL LIGHTER
GB201915485D0 (en) Improvements in or relaing to cognitive function
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof